pirenzepine has been researched along with Adenocarcinoma in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Baba, M | 1 |
| Yano, H | 1 |
| Uehara, H | 1 |
| Nakaizumi, A | 1 |
1 other study available for pirenzepine and Adenocarcinoma
| Article | Year |
|---|---|
Effect of selective and non-selective muscarinic blockade on baclofen inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
Topics: Adenocarcinoma; Animals; Atropine; Baclofen; Bromodeoxyuridine; Carcinogens; GABA Agonists; Male; Me | 1996 |